April 9th 2024
If the company' experimental agent is approved, it would join Humira (adalimumab), Rinvoq (upadacitinib) and Skyrizi (risankizumab) in AbbVie's portfolio.
Studies have shown that the use of oral corticosteroids in patients with UC is associated with higher rates of adverse effects and use of healthcare resources compared with biologics or immunosuppressants. However, there is little research focusing on the economic and clinical burden of chronic corticosteroid use among people living with UC.
Read More
Noninvasive Blood-based Model Developed to Assess Extent and Severity of Ulcerative Colitis
December 18th 2023In an effort to reduce financial and other quality of life burdens for individuals living with ulcerative colitis, Hongliang Chen and his colleagues from the Department of Gastroenterology and Hepatology at four medical centers in northeast China sought to develop a routine blood-based tool for assessing the extent and severity of ulcerative colitis.
Read More
FDA Approves First-in-Class Therapy for Ulcerative Colitis
October 27th 2023Mirikizumab — now with the brand name — Omvoh is the first therapy that targets interleukin-23p19, which plays a role in inflammation. It has a list price of $9,593 per month for the IV formulation and $10,360 per subcutaneous administration.
Read More
Chances of Developing Gout Are Higher for Patients With IBD
September 28th 2023Study links inflammatory bowel disease diagnosis to increased gout risk, with Crohns disease and ulcerative colitis linked to 68% and 38% increases in likelihood of developing gout, respectively, relative to counterparts without IBD.
Read More
Research has shown that patients with inflammatory bowel disease, including ulcerative colitis, treated with TNF-alpha blockers have a lower antibody response and a shorter duration of immunity than those who receive integrin receptor antagonists, such as Entyvio (vedolizumab), or no medication at all.
Read More
Statin Use May Lower Risk of Colorectal Cancer in Patients with Ulcerative Colitis
September 8th 2023In an observational cohort study published in the September 2023 issue of The Lancet, Jiangwei Sun, Ph.D., from the Karolinska Institutet in Stockholm, Sweden, and his colleagues compared statin users with non-statin users to determine the risk of colorectal cancer in patients with IBD.
Read More
Interleukin-2 Found to Be a Promising Pathway to Treat Ulcerative Colitis
August 7th 2023A small, open-label study seeds the idea that IL-2 in low doses might be another avenue for treating ulcerative colitis. Low doses may bolster anti-inflammatory T regulatory cells (Tregs) that are believed to lack sufficient expansion in the disease.
Read More
A Step Forward, Perhaps, for Safe Step Act and Exemptions from Step Therapy
June 19th 2023Legislation designed to smooth the path to exemptions from step therapy has been incorporated into the Pharmacy Benefit Reform Act, one of several bills targeting pharmacy benefit managers that is making legislative headway in the Senate.
Read More